Pharmacodynamics of combined estrogen-progestin oral contraceptives 3. Inhibition of ovulation

  title={Pharmacodynamics of combined estrogen-progestin oral contraceptives 3. Inhibition of ovulation},
  author={Carlo Bastianelli and Manuela Farris and Elena Rosato and Ivo Brosens and Giuseppe Benagiano},
  journal={Expert Review of Clinical Pharmacology},
  pages={1085 - 1098}
ABSTRACT Introduction: Following a historical overview, the ovulation-inhibiting effect of various orally administered estrogen-progestin combinations (combined oral contraceptives [COCs]) are examined for their components alone or in the various combined formulations. Special emphasis is given to products containing natural estrogens. Areas covered: Inhibition of ovulation with progestins alone; estrogens alone; various progestins in combination with ethinyl estradiol; various progestins in… 

Determining the Exposure Threshold for Levonorgestrel Efficacy Using an Integrated Model Based Meta‐Analysis Approach

The results suggest that the use of backup or alternate methods of contraception is not necessarily required for oral LNG + EE formulations except within circumstances of both obesity and strong CYP3A4 inducer concomitance following administration of LNG100.

Estetrol/Drospirenone: A Review in Oral Contraception

Estetrol/drospirenone is an effective and generally well-tolerated COC, with a potentially reduced risk of thrombosis, and may offer a contraceptive option with a lower risk for blood clots.

Chemical contraceptive impacts on cyclic progesterone and sexual behavior in zoo-housed Western lowland gorillas.

There is a need for additional research on contraceptive use in gorillas and the effects on cyclic progesterone and timing of sexual behaviors have not been well studied, which reinforces that sexual behavior in gorilla is both hormonally and socially mediated.

Unintended pregnancy in users of nomegestrol acetate and 17β-oestradiol (NOMAC-E2) compared with levonorgestrel-containing combined oral contraceptives: final results from the PRO-E2 study

  • S. ReedC. Koro K. Heinemann
  • Medicine
    The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2021
NOMAC-E2 demonstrated superior contraceptive effectiveness compared to COCLNG, likely due to the comparatively short hormone-free interval and possibly reinforced by the long half-life of NOMAC.

Comparison of the Efficacy and Tolerability of Dienogest and Dienogest Plus Ethinylestradiol on Endometriosis Related-Pain

Estrogen-progestin and a progestin alone seem to be of similar efficacy for the temporary treatment of endometriosis-related pain and the dienogest plus ethinylestradiol combination was slightly less effective on deep dyspareunia but was still well tolerated.

A safety evaluation of current medications for adult women with the polycystic ovarian syndrome not pursuing pregnancy

There is no solid evidence supporting that the use of combined oral contraceptives in women with PCOS increases the risk of cardiovascular or thromboembolic events compared with the general population.

Case-based discussion on the implications of exogenous estrogens in hemostasis and thrombosis: the obstetrician's view.

  • A. James
  • Medicine
    Hematology. American Society of Hematology. Education Program
  • 2019
This is the obstetrician's view on 3 different clinical scenarios involving bleeding and thrombotic disorders. In the first scenario, an 18 year old with a history of heavy menstrual bleeding since

Current treatment for Polycystic Ovary Syndrome: focus on adolescence.

Emerging data support inositol and alpha-lipoic acid as alternative compounds, alone or in combination with the aforementioned strategies, with favourable effects on ovulation, insulin resistance and inflammation, and additional studies are required in adolescents, in order to assess the effectiveness of diet supplements in preventing negative impacts of PCOS on fertility in adult age.

The attention-emotion interaction in healthy female participants on oral contraceptives during 1-week escitalopram intake

1 week of escitalopram administration may not modulate attention toward negative emotional distractors outside the focus of attention in healthy female participants taking OCs, and the results represent a valuable contribution toward the preclinical investigation of antidepressant treatment.



Estrogens in oral contraceptives: historical perspectives.

  • J. Goldzieher
  • Medicine, Biology
    The Johns Hopkins medical journal
  • 1982
Clinical studies with continuous low-dose progestin only formulations have demonstrated that their effectiveness in inhibiting ovulation is substantially lower than that of sequential or combination type preparations, and the predicted mortality from cardiovascular disease in OC users confirmed.

Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills.

  • R. Sitruk-WareA. Nath
  • Medicine, Biology
    Best practice & research. Clinical endocrinology & metabolism
  • 2013

Pharmacological and endocrine profiles of gestodene.

Modulation by gestodene of luteinizing hormone-releasing hormone (LH-RH)-stimulated gonadotropin release in vitro and in vivo in a rat model system indicated that gestodenes is some three times as biologically active as levonorgestrel.

Pharmacology of estrogens and progestogens: influence of different routes of administration

  • H. Kuhl
  • Medicine, Biology
    Climacteric : the journal of the International Menopause Society
  • 2005
This review comprises the pharmacokinetics and pharmacodynamics of natural and synthetic estrogens and progestogens used in contraception and therapy, with special consideration of hormone

Comparative studies of the ethynyl estrogens used in oral contraceptives. II. Antiovulatory potency.

New knowledge in the physiology of hormonal contraceptives


Endogenous estradiol metabolism during treatment with oral contraceptives.

OCs containing norethisterone acetate, dienogest or levonorgestrel did not have a negative effect on estradiol metabolism, i.e. they did not elicit a higher D-ring metabolism, which is considered to increase breast cancer risk.

The History of Steroidal Contraceptive Development: The Estrogens

  • J. Goldzieher
  • Medicine, Biology
    Perspectives in biology and medicine
  • 1993
Our understanding of estrogenic activity began in 1912, when Adler and Fellner in Vienna and Iscovesco in Paris obtained the first ovarian extracts and Haberlandt concluded that ovarian